



NMDP is finding cures and saving lives

NMDPSM is accelerating the journey to a world where blood cancer and other rare diseases are a thing of the past.

- Every 3-4 minutes someone in the U.S. is diagnosed with a blood cancer.
- Every year, 18,000 patients are diagnosed with life-threatening blood cancers or other diseases for which a blood stem cell transplant may be their best or only hope for a cure.
- 75+ diseases—including leukemia, lymphoma, aplastic anemia, sickle cell and immune-deficiency disorders—can be cured or treated from blood stem cells.

Members and Donors: Their good goes a long way

At NMDP, we're unlocking new treatments with unprecedented life-saving potential all the time—and our members, who make the NMDP RegistrySM the world's most diverse blood stem cell donor registry, are essential to our work.

- NMDP facilitates all unrelated transplants in the U.S., assisting transplant doctors in searching more than 42 million potential donors worldwide.
- More than 9 million total potential U.S. donors are on the NMDP Registry.
- There is no cost for members to donate to unrelated patients. All donor expenses are covered by NMDP, including medical and travel expenses, lost wage reimbursement and even child or pet care.

Who is eligible to join the NMDP Registry?

To join the NMDP Registry individuals must be 18-40 years old and a resident of the United States or one of its territories or freely associated states. To register, visit nmdp.org, complete a health history form and a cheek swab kit will be sent via mail. Once the swab kit is returned, it is typed and the individual added to the registry.

**7,994 lives
impacted by
NMDP In 2024**

**More than
140,000
transplants
facilitated
since 1987**

**75% of patients
don't have a fully
matched donor
in their family**

People between the ages of 18 and 35 are most urgently needed. Research has shown that cells from younger donors lead to better long-term survival for patients.

In addition, to continue to help diversify the registry and help more patients, more young people of diverse racial and ethnic heritage are needed.

How Is someone chosen to be a donor?

When doctors determine a patient needs a blood stem cell transplant, they search the NMDP Registry to identify a donor who best matches genetic markers called human leukocyte antigens, or HLA markers. The markers are inherited, so donors and patients are likely to share the same ethnic background. Because of the genetic complexity of matching donors to patients, it could be months or years before a registry member is called to donate.

Unfortunately, less than half of potential donors say “Yes” to donate when asked to donate. When someone joins the NMDP Registry, remaining committed to donating to any patient in the world is critical and ensures patients are given their best chance at finding a cure.

What is the donation process?

A blood stem cell transplant replaces a patient’s unhealthy blood-forming cells with healthy ones from their donor. The cells used in transplants come from three sources: peripheral blood stem cells (PBSC), marrow and umbilical cord blood.



Adults may be asked to donate one of two ways. The patient’s doctor chooses the donation method that’s best for the patient.

- About 90 percent of the time, blood stem cells are collected via PBSC, a non-surgical, outpatient procedure similar to donating platelets or plasma. This process requires 5 days of shots leading up to donation to increase the production of blood-forming cells.
- About 10 percent of the time, doctor’s request marrow donation, which is a surgical procedure performed under general anesthesia. Doctors use a needle to withdraw liquid marrow (where the body’s blood-forming cells are made) from the pelvic bone.

A third source of cells used in transplants is cord blood, which is collected from the umbilical cord and placenta immediately after a baby is born. It is stored at a public cord blood bank and the cord blood unit is listed on the NMDP Registry. There is no cost for parents to donate cord blood.

NMDP Registry members can help shape the future of medicine

At NMDP we’re creating a future in which one donation of regenerative cells will save countless lives, all over the world. NMDP BioTherapiesSM leads groundbreaking research to advance patient treatments—and NMDP Registry members can be part of it. Members can opt-in and if eligible have the potential to save hundreds of lives with a single blood stem cell donation.



Patients: Guidance throughout their journey

Patients are the heart of what we do at NMDP. From clinical trials to counseling and peer programs, NMDP has the tools and resources to support patients and their loved ones along the journey. NMDP’s team of patient navigators offer support to thousands of patients and caregivers each year as they consider or prepare to go to transplant by:

- Explaining and reviewing insurance questions
- Discussing logistics of transplants—from preparation to caregivers and housing
- Addressing fears and providing comfort through social worker counseling
- Connecting patients to transplant recipients through the NMDP Peer Connect program
- Assessing treatment options through our Jason Carter Clinical Trial Search and Support program
- **Offering patient assistance (\$6.6 million provided to 3,300 families in 2024) to support costs not covered by insurance.**

Volunteers: Their innate goodness turned into a limitless, life-saving gift

Whether supporting a registry drive, transporting life-saving blood stem cells or advocating for policy changes, NMDP relies on volunteers who choose to invest their time with an organization that’s helping to make blood cancer and other rare diseases a thing of the past.

For example, a team of more than 500 volunteer couriers hand-deliver blood stem cells from donors to patients across the globe. Last year the couriers spent more than 138,090 volunteer hours on more than 4,618 trips.

Partners: A global movement to save lives

NMDP strives to deliver world-class service to transplant centers, donor centers and biotherapies partners by providing decision-making tools, high-quality products and research data to deliver clinical excellence and advance standards of care for patients and donors. As a member of the World Marrow Donor Association, NMDP collaborates across an extensive global ecosystem of experts and organizations.

| | DOMESTIC | GLOBAL |
|--------------------------|----------|--------|
| Apheresis centers | 62 | 6 |
| Collection centers | 46 | 5 |
| Cooperative registries | NA | 48 |
| Donor centers | 4 | 15 |
| Member cord blood banks | 16 | 0 |
| Testing labs | 8 | NA |
| Transplant centers | 157 | 52 |
| Research center partners | 213 | 142 |

| |
|--|
| Number of countries outside the United States with donor centers, transplant centers and other registries that have relationships with NMDP: 45 |
| Number of apheresis centers, collection centers, cooperative registries, donor centers, member cord blood banks and transplant centers in NMDPs network: 363 |

¹Salesforce CRM; CIBMTR DISCO database, December 2022; HRSA Report

Research: Advancing cell therapy to save more lives

Researchers are seeking a breakthrough; providers are seeking options; and NMDP is accelerating innovation to reduce relapse rates, minimize the impact of graft versus host disease (GVHD) and increase access to cell therapy for all patients.

CIBMTR® a research collaboration between NMDP and the Medical College of Wisconsin, invests more than \$77 million annually in research and facilitates 250 ongoing studies and clinical trials annually in cooperation with 310 global transplant centers.

CIBMTR offers one of the world’s largest databases of cell therapy patient outcomes, including data collected from more than 700,000 global transplant recipients and a Research Sample Repository containing 2.6 million sample aliquots from related and unrelated transplant donors, cord blood units, and recipients.

Research spotlight: Donor for All

Over the past three years, NMDP has led extensive research through its Donor for All initiative to deliver equitable outcomes for patients without a fully matched donor on the registry, often due to their ethnic background. For Black or African American or mixed race patients currently facing the lowest odds of finding a fully matched donor, this research points to the possibility for a nearly three-fold increase in the likelihood of securing a suitable donor and offering transplant as a viable, life-saving cell therapy. Several studies explored the use of a novel post-transplant treatment to prevent GVHD, which poses the greatest risk to patients without fully matched donors. The studies show this treatment can deliver outcomes with no discernible difference using a 7/8 donor compared to a fully matched 8/8 donor.² If implemented as a standard of care, the results will be transformational.

| Odds of finding a matched available donor by patient ethnic background | | |
|--|-----|-----|
| | 7/8 | 8/8 |
| Asian or Pacific Islander | 92% | 47% |
| Black or African American | 84% | 29% |
| Hispanic or Latino | 90% | 48% |
| Native American | 93% | 60% |
| White | 98% | 79% |

²Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies



ABOUT NMDPSM

At NMDP, we believe each of us holds the key to curing blood cancers and disorders. As a global nonprofit leader in cell therapy, NMDP creates essential connections between researchers and supporters to inspire action and accelerate innovation to find life-saving cures.

With the help of blood stem cell donors from the world’s most diverse registry and our extensive network of transplant partners, physicians and caregivers, we’re expanding access to treatment so that every patient can receive their life-saving cell therapy. NMDP. Find cures. Save lives.

OUR MISSION

We save lives through cell therapy.

OUR VISION

Create a world where **every** patient can receive their life-saving cell therapy.